DICE Therapeutics
Melissa Vega has work experience in various roles and companies. In 2017, they worked as a Wellness Coordinator for The Joint Chiropractic until 2019. In 2021, they joined BioCheck, Inc. as a Laboratory Technician from August to October, and then joined Freenome as a Laboratory Technician I from November 2021 to May 2022. Currently, Melissa is working at DICE Therapeutics as a Research Associate 1, starting in August 2022.
Melissa Vega earned their Bachelor's degree in Molecular Biology from Humboldt State University, where they studied from 2019 to 2021. Prior to that, they attended Los Medanos College, where they pursued an Associate of Science degree in Biology, with a focus on General Biology. The specific start and end dates for this period of education are not provided.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.